Colorectal cancer remains a significant cause of morbidity and mortality worldwide. Half of all patients develop liver metastases, presenting unique challenges for their treatment. The shortcomings of conventional chemotherapy has encouraged the use of nanomedicines; the application of nanotechnology in the diagnosis and treatment of disease. In spite of technological improvements in nanotechnology, the complexity of biological systems hinders the prospect of nanomedicines being applied in cancer therapy at the present time. This review highlights current biological barriers and discusses aspects of tumor biology together with the physicochemical features of the nanocarrier, that need to be considered in order to develop effective nanotherapeutics for colorectal cancer patients with liver metastases. It becomes clear that incorporating an interdisciplinary approach when developing nanomedicines should assure appropriate disease-driven design and that this will form a critical step in improving their clinical translation. This article is characterized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.

中文翻译：

---

使用纳米技术靶向结直肠肝转移的关键考虑因素。


结直肠癌仍然是全世界发病和死亡的重要原因。一半的患者出现肝转移，这给他们的治疗带来了独特的挑战。传统化疗的缺点鼓励了纳米药物的使用；纳米技术在疾病诊断和治疗中的应用。尽管纳米技术不断进步，但生物系统的复杂性阻碍了纳米药物目前在癌症治疗中应用的前景。这篇综述强调了当前的生物障碍，并讨论了肿瘤生物学的各个方面以及纳米载体的物理化学特征，为了开发针对肝转移的结直肠癌患者的有效纳米疗法，需要考虑这些特征。很明显，在开发纳米药物时采用跨学科方法应确保适当的疾病驱动设计，这将成为改善其临床转化的关键一步。本文的特点是：治疗方法和药物发现>肿瘤疾病的纳米医学。